CRIS Current Research Information System

IACOBUCCI, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.196
AS - Asia 15.191
EU - Europa 12.175
SA - Sud America 932
AF - Africa 926
Continente sconosciuto - Info sul continente non disponibili 810
OC - Oceania 20
Totale 47.250
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.856
SG - Singapore 4.031
CN - Cina 3.960
VN - Vietnam 3.886
GB - Regno Unito 3.471
SE - Svezia 1.989
IT - Italia 1.498
DE - Germania 1.464
HK - Hong Kong 880
IN - India 808
FR - Francia 760
BR - Brasile 632
RU - Federazione Russa 627
NL - Olanda 409
IE - Irlanda 404
UA - Ucraina 363
ZA - Sudafrica 311
JP - Giappone 301
KR - Corea 244
EE - Estonia 236
BD - Bangladesh 218
CA - Canada 192
CH - Svizzera 191
FI - Finlandia 185
TG - Togo 183
GR - Grecia 164
CI - Costa d'Avorio 149
AR - Argentina 123
PH - Filippine 116
NG - Nigeria 115
BG - Bulgaria 108
JO - Giordania 102
IR - Iran 96
ID - Indonesia 75
SC - Seychelles 75
TR - Turchia 70
TH - Thailandia 64
IQ - Iraq 61
BE - Belgio 60
PL - Polonia 58
ES - Italia 48
AT - Austria 47
MX - Messico 47
EC - Ecuador 42
TW - Taiwan 41
SA - Arabia Saudita 38
CO - Colombia 36
PK - Pakistan 31
MY - Malesia 30
UZ - Uzbekistan 30
VE - Venezuela 29
LB - Libano 22
CL - Cile 20
JM - Giamaica 20
CZ - Repubblica Ceca 18
PE - Perù 18
PY - Paraguay 18
AU - Australia 17
EG - Egitto 17
HN - Honduras 15
KE - Kenya 15
TN - Tunisia 13
AE - Emirati Arabi Uniti 12
HR - Croazia 12
KZ - Kazakistan 12
MA - Marocco 12
RO - Romania 11
EU - Europa 10
NI - Nicaragua 10
ET - Etiopia 9
LT - Lituania 9
PA - Panama 9
TM - Turkmenistan 9
CR - Costa Rica 8
DZ - Algeria 8
GT - Guatemala 8
RS - Serbia 8
IL - Israele 7
AL - Albania 6
MD - Moldavia 6
MU - Mauritius 6
OM - Oman 6
PR - Porto Rico 6
GY - Guiana 5
SK - Slovacchia (Repubblica Slovacca) 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
BB - Barbados 4
BO - Bolivia 4
KG - Kirghizistan 4
NP - Nepal 4
PS - Palestinian Territory 4
PT - Portogallo 4
QA - Qatar 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
AM - Armenia 3
AO - Angola 3
GP - Guadalupe 3
NZ - Nuova Zelanda 3
Totale 46.398
Salva come PNG Salva come JPEG
Città #
Southend 3.194
Singapore 2.789
Ashburn 1.600
Fairfield 1.500
Chandler 1.312
San Jose 1.041
Dong Ket 981
Hong Kong 836
Houston 832
Wilmington 756
Woodbridge 721
Seattle 651
Beijing 608
Ho Chi Minh City 603
Princeton 599
Ann Arbor 564
Hanoi 543
Hefei 531
Santa Clara 528
Cambridge 506
Dublin 403
Boardman 384
Westminster 296
Council Bluffs 291
Lauterbourg 291
Nanjing 290
Padova 263
Bologna 247
Tokyo 245
Los Angeles 241
New York 209
Lomé 183
Seoul 179
Medford 170
Bern 158
Dallas 158
Helsinki 157
Jacksonville 157
Jinan 154
Abidjan 149
Shenyang 144
Saint Petersburg 134
Berlin 130
Buffalo 116
Milan 109
Hebei 105
Nanchang 105
Sofia 105
Changsha 104
Amman 101
San Diego 98
São Paulo 97
Frankfurt am Main 96
Redondo Beach 96
Munich 92
Redmond 86
Da Nang 83
Haiphong 80
Turin 80
Tianjin 78
Falls Church 77
Bremen 75
Chicago 72
Shanghai 72
Abeokuta 70
Guangzhou 68
Zhengzhou 65
Florence 62
Jiaxing 60
Hangzhou 59
Brussels 58
Phoenix 58
Toronto 52
Bengaluru 51
Mülheim 51
Norwalk 51
Rome 51
Orem 50
Haikou 49
Redwood City 48
Ningbo 41
Athens 36
Warsaw 36
Baghdad 35
Istanbul 35
London 35
Mountain View 35
Bangkok 34
Hải Dương 34
Kunming 34
Taiyuan 34
Taizhou 34
San Francisco 33
Amsterdam 32
Jakarta 30
Johannesburg 30
Mahé 30
Montreal 30
Vienna 30
Dearborn 29
Totale 29.225
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 413
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 360
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 360
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 350
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 350
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 326
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 325
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 323
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 319
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 312
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 310
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 306
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 289
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 283
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 283
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 273
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 271
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 262
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 258
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 254
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 251
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 248
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 246
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 237
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 236
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 236
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 233
Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial 233
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 231
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 229
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 227
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 227
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 227
A case report of acute myeloid leukemia and neurofibromatosis 1 225
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 224
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 223
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 222
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 221
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 220
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 220
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 216
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 215
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 215
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 215
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia 214
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 212
RALE051: a novel established cell line of sporadic Burkitt lymphoma 212
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 211
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 207
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 207
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 207
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 206
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 206
c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration 205
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 202
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 200
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. 199
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 199
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 198
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 198
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 197
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 197
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. 196
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 194
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 193
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 192
The cell cycle checkpoint inhibitors in the treatment of leukemias 191
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 191
Association between transporters genotype and response to the treatment in a subset of previously untreated chronic myeloid leukemia patients enrolled into the tops trial. 190
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 190
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 190
Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model 189
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 189
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 189
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 188
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 186
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 186
EFFICACY AND FEASIBILITY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): A SINGLE-CENTER EXPERIENCE 186
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 184
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 184
AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. 182
Clec12a: A new AML stem cell-associated antigen 182
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 182
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 181
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 181
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 180
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 180
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 178
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 178
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 177
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 177
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 176
Identification of Rab5 as a Gene Involved in Chronic Myeloid Leukemia (CML) Progression 174
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables 174
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 174
Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia 174
Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients 172
SNP array reveals a new deletion of JAK2 in AML patients 172
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 171
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 170
Totale 22.324
Salva come PNG Salva come JPEG
Categoria #
all - tutte 124.482
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 124.482
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.860 0 0 403 489 576 397 104 364 273 397 917 940
2022/20235.645 685 919 291 734 391 440 184 329 870 126 400 276
2023/20241.460 63 241 62 123 105 355 110 81 61 63 87 109
2024/20255.384 230 879 459 356 815 281 392 144 43 494 198 1.093
2025/202613.082 927 1.116 1.196 818 1.436 775 1.258 669 2.823 1.158 507 399
2026/20271.497 364 551 582 0 0 0 0 0 0 0 0 0
Totale 47.250